---
title: 'Development and Preclinical Evaluation of [<sup>211</sup>At]PSAt-3-Ga: An
  Inhibitor for Targeted α-Therapy of Prostate Cancer'
date: '2024-02-29'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38423784/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240301170524&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'The application of prostate-specific membrane antigen (PSMA)-targeted
  α-therapy is a promising alternative to β^(-)-particle-based treatments. ^(211)At
  is among the potential α-emitters that are favorable for this concept. Herein, ^(211)At-based
  PSMA radiopharmaceuticals were designed, developed, and evaluated. Methods: To identify
  a ^(211)At-labeled lead, a surrogate strategy was applied. Because astatine does
  not exist as a stable nuclide, it is commonly replaced with iodine to mimic ...'
disable_comments: true
---
The application of prostate-specific membrane antigen (PSMA)-targeted α-therapy is a promising alternative to β^(-)-particle-based treatments. ^(211)At is among the potential α-emitters that are favorable for this concept. Herein, ^(211)At-based PSMA radiopharmaceuticals were designed, developed, and evaluated. Methods: To identify a ^(211)At-labeled lead, a surrogate strategy was applied. Because astatine does not exist as a stable nuclide, it is commonly replaced with iodine to mimic ...